Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
The US Federal Trade Commission said that CVS Health's Caremark, Cigna's Express Scripts, and UnitedHealth Group's Optum ...
The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made ...
Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...
These snack recipes are lower in sodium, saturated fat, carbs and calories, making them good choices for managing insulin ...
WASHINGTON, September 23, 2024--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) applauds the U.S. Federal Trade Commission (FTC) for taking decisive action against pharmacy benefit managers (PBMs) ...
As a special education teacher living with Type 1 diabetes in Crawfordsville, I’ve relied on insulin to manage my condition since my diagnosis in 2011. Despite my engagement as an #insulin4all ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback